Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review

References

• World Health Organization, Cancer Fact Sheet No. 297, (2017). [cited 2018 Feb 1]. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/).
   Google Scholar
• Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest. 2005;128:452–462.
   PubMed Web of Science ®Google Scholar
• Goya T, Asamura H, Yoshimura H, et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 2005;50:227–234.
   PubMed Web of Science ®Google Scholar
• Eberhardt WE, De Ruysscher D, Weder W, et al. 2nd ESMO Consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–1588.
   PubMed Web of Science ®Google Scholar
• O’Rourke N, Roque IFM, Farre Bernado N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010;6:CD002140.
   PubMed Web of Science ®Google Scholar
• Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2181–2190.
   PubMed Web of Science ®Google Scholar
• Ahn JS, Ahn YC, Kim JH, et al. Multinational randomized Phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable Stage III non-small-cell lung cancer: KCSG-LU05-04. J Clin Oncol. 2015;33:2660–2666.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–1929.
   PubMed Web of Science ®Google Scholar
• [cited 2018 May 25]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html
   Google Scholar
• Barletta G, Genova C, Rijavec E, et al. Oral vinorelbine in the treatment of non-small-cell lung cancer. Expert Opin Pharmacother. 2014;15:1585–1599.
   PubMed Web of Science ®Google Scholar
• Zatloukal P, Petruzelka L, Zemanova M, et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer. 2004;46:87–98.
   PubMed Web of Science ®Google Scholar
• Hirose T, Mizutani Y, Ohmori T, et al. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer. Cancer Chemother Pharmacol. 2006;58:361–367.
   PubMed Web of Science ®Google Scholar
• Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol. 2006;1:810–815.
   PubMed Web of Science ®Google Scholar
• Leong SS, Fong KW, Lim WT, et al. A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer. 2010;67:325–329.
   PubMed Web of Science ®Google Scholar
• Lin Q, Liu Y, Wang N, et al. A modified Phase I trial of radiation dose escalation in 3D conformal radiation therapy with concurrent vinorelbine and carboplatin chemotherapy for non-small-cell lung cancer. J Radiat Res. 2013;54:126–134.
   PubMed Web of Science ®Google Scholar
• Fournel P, Vergnenegre A, Robinet G, et al. Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01. Eur J Cancer. 2016;52:181–187.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Wang Z, Huang W, et al. Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer. Oncotarget. 2016;7:8422–8431.
   PubMedGoogle Scholar
• Hughes BG, Ahern E, Lehman M, et al. Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study. Asia Pac J Clin Oncol. 2017;13:137–144.
   PubMed Web of Science ®Google Scholar
• Genestreti G, Grossi F, Genova C, et al. Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview. Future Oncol. 2014;10:2081–2096.
   PubMed Web of Science ®Google Scholar
• Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf. 2005;4:915–928.
   PubMedGoogle Scholar
• Beckmann G, Fietkau R, Huber RM, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small cell lung cancer (NSCLC): a feasibility study. Onkologie. 2006;29:137–142.
   PubMedGoogle Scholar
• Perri F, Lazzari G, Della Vittoria Scarpati G, et al. Oral vinorelbine: a feasible and safe partner for radiotherapy in the treatment of locally advanced non-small cell lung cancer. Onco Targets Ther. 2016;9:2359–2364.
   PubMed Web of Science ®Google Scholar
• Krzakowski M, Provencio M, Utracka-Hutka B, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol. 2008;3:994–1002.
   PubMed Web of Science ®Google Scholar
• Descourt R, Vergnenegre A, Barlesi F, et al. Oral vinorelbine and cisplatin with concurrent radiotherapy after induction chemotherapy with cisplatin and docetaxel for patients with locally advanced non-small cell lung cancer: the GFPC 05-03 study. J Thorac Oncol. 2011;6:351–357.
   PubMed Web of Science ®Google Scholar
• Strom HH, Bremnes RM, Sundstrom SH, et al. Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer. 2013;109:1467–1475.
   PubMed Web of Science ®Google Scholar
• Strom HH, Bremnes RM, Sundstrom SH, et al. How do elderly poor prognosis patients tolerate palliative concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer Stage III? A subset analysis from a clinical Phase III trial. Clin Lung Cancer. 2015;16:183–192.
   PubMed Web of Science ®Google Scholar
• Strom HH, Bremnes RM, Sundstrom SH, et al. Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial. J Thorac Oncol. 2014;9:825–833.
   PubMed Web of Science ®Google Scholar
• Juan O, Sanchez-Hernandez A, Vazquez S, et al. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: a multi-center phase II study. Anticancer Res. 2014;34:1959–1966.
   PubMed Web of Science ®Google Scholar
• Lerouge D, Riviere A, Dansin E, et al. A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer. BMC Cancer. 2014;14:231.
   PubMed Web of Science ®Google Scholar
• Singhal N, Mislang A, Karapetis CS, et al. Oral vinorelbine and cisplatin with concomitant radiotherapy in stage III non-small-cell lung cancer: an open-label phase II multicentre trial (COVeRT study). Anticancer Drugs. 2015;26:1083–1088.
   PubMed Web of Science ®Google Scholar
• Flentje M, Huber RM, Engel-Riedel W, et al. GILT – a randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer. Strahlenther Onkol. 2016;192:216–222.
   PubMed Web of Science ®Google Scholar
• Costa Rivas M, Huidobro Vence G, Firvida Perez JL, et al. Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group. Clin Transl Oncol. 2018 April 25 doi: 10.1007/s12094-018-1880.
   PubMedGoogle Scholar
• Locher C, Pourel N, Le Caer H, et al. Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small–cell lung cancers: an open phase II study using concurrent cisplatin–oral vinorelbine and radiotherapy (GFPC 08-06). Lung Cancer. 2018;121:25–29.
   PubMed Web of Science ®Google Scholar
• Isla D, Majem M, Guirado M, et al. NORA trial (GECP 15/02): first efficacy results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC). J Clin Oncol. 2018;36:8537.
   Web of Science ®Google Scholar
• Chiu W-H, Chen HH-W, Su W-C. Oral vinorelbine: a better choice for concurrent chemoradiotherapy in stage III non-small cell lung cancer. J Solid Tumors. 2012;2:4.
   Google Scholar
• Scotti V, Saieva C, Di Cataldo V, et al. Vinorelbine-based chemo-radiotherapy in non-small cell lung cancer. Tumori. 2012;98:464–470.
   PubMed Web of Science ®Google Scholar
• Schwarzenberger P, Fariss A, Linares L, et al. Dose escalation of once weekly oral vinorelbine concurrent with weekly split dose hypofractionated chest radiation for palliation of advanced non-small cell lung cancer: a phase I/II study. Am J Med Sci. 2011;341:454–459.
   PubMed Web of Science ®Google Scholar
• Hansen O, Knap MM, Khalil A, et al. A randomized phase II trial of concurrent chemoradiation with two doses of radiotherapy, 60Gy and 66Gy, concomitant with a fixed dose of oral vinorelbine in locally advanced NSCLC. Radiother Oncol. 2017;123:276–281.
   PubMed Web of Science ®Google Scholar
• Bezjak A, Temin S, Franklin G, et al. Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology evidence-based clinical practice guideline. J Clin Oncol. 2015;33:2100–2105.
   PubMed Web of Science ®Google Scholar
• Vokes EE, Herndon JE 2nd, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002;20:4191–4198.
   PubMed Web of Science ®Google Scholar
• Gnoni A, Silvestris N, Licchetta A, et al. Metronomic chemotherapy from rationale to clinical studies: a dream or reality? Crit Rev Oncol Hematol. 2015;95:46–61.
   PubMed Web of Science ®Google Scholar
• Pallis AG, Chandrinos V, Pavlakou G, et al. A multicenter phase I trial of metronomic oral vinorelbine plus cisplatin in patients with NSCLC. Cancer Chemother Pharmacol. 2011;67:1239–1245.
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Aravantinos G, Kouvatseas G, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer; a hellenic cooperative oncologyl group clinical translational study. Bmc Cancer. 2013;13:263.
   PubMed Web of Science ®Google Scholar
• Camerini A, Puccetti C, Donati S, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15:359.
   PubMed Web of Science ®Google Scholar
• Katsaounis P, Kotsakis A, Agelaki S, et al. Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG). Cancer Chemother Pharmacol. 2015;75:821–827.
   PubMed Web of Science ®Google Scholar
• Briasoulis E, Aravantinos G, Kouvatseas G, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a Hellenic Cooperative Oncology Group clinical translational study. BMC Cancer. 2013;13:263.
   PubMed Web of Science ®Google Scholar
• Kontopodis E, Hatzidaki D, Varthalitis I, et al. A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group. J Chemother. 2013;25:49–55.
   PubMed Web of Science ®Google Scholar
• Cazzaniga ME, Camerini A, Addeo R, et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncol. 2016;12:373–387.
   PubMed Web of Science ®Google Scholar
• Pasini F, Barile C, Caruso D, et al. Oral metronomic vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world. Invest New Drugs. 2018;28(Jun). [ Epub ahead of print]. doi:10.1007/s10637-018-0631-8
   Google Scholar
• Biziota E, Mavroeidis L, Hatzimichael E, et al. Metronomic chemotherapy: a potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett. 2017;400:243–251.
   PubMed Web of Science ®Google Scholar
• Orlandi P, Di Desidero T, Salvia G, et al. Metronomic vinorelbine is directly active on non small cell lung cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochem Pharmacol. 2018;152:327–337.
   PubMed Web of Science ®Google Scholar
• Altinoz MA, Ozpinar A, Alturfan EE, et al. Vinorelbine’s anti-tumor actions may depend on the mitotic apoptosis, autophagy and inflammation: hypotheses with implications for chemo-immunotherapy of advanced cancers and pediatric gliomas. J Chemother. 2018;20:1–10.
   Google Scholar